cabergoline has been researched along with Disruptive, Impulse Control, and Conduct Disorders in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamidianjahromi, A; Tritos, NA | 1 |
| Durcan, E; Kadioglu, P; Kavla, Y; Ozkaya, HM; Özogul, YY; Poyraz, BC; Sahin, S; Sayitoglu, M; Sudutan, T | 1 |
| Ciftci, S; Ersungur, EB; Gul, N; Kadioglu, P; Ozkaya, HM; Poyraz, BC; Sahin, S; Sarac, B; Sulu, C; Tanrikulu, S; Tanriover, E; Yener Ozturk, F | 1 |
| Beccuti, G; Cambria, V; Cicolin, A; Ghigo, E; Grottoli, S; Guaraldi, F; Lopiano, L; Montanaro, E; Natta, G; Prencipe, N; Zibetti, M | 1 |
| Bulwer, C; Conn, R; Ederies, A; Ferrau, F; Kapur, S; Korbonits, M; Shankar, A; Spoudeas, HA | 1 |
1 review(s) available for cabergoline and Disruptive, Impulse Control, and Conduct Disorders
| Article | Year |
|---|---|
Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.
Topics: Bromocriptine; Cabergoline; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms | 2022 |
4 other study(ies) available for cabergoline and Disruptive, Impulse Control, and Conduct Disorders
| Article | Year |
|---|---|
A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients With Prolactinoma.
Topics: Cabergoline; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Pituitary Neoplasms; Prolactinoma; Serotonin Plasma Membrane Transport Proteins | 2023 |
Risk of impulse control disorders in patients with Cushing's disease: do not blame cabergoline but do not give up caution.
Topics: Cabergoline; Cross-Sectional Studies; Depressive Disorder, Major; Disruptive, Impulse Control, and Conduct Disorders; Humans; Pituitary ACTH Hypersecretion; Prospective Studies | 2023 |
Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study.
Topics: Behavioral Symptoms; Cabergoline; Cross-Sectional Studies; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Italy; Male; Middle Aged; Pituitary Diseases; Prevalence; Risk Factors; Surveys and Questionnaires | 2021 |
Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma.
Topics: Adolescent; Cabergoline; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Pituitary Neoplasms; Prolactinoma | 2017 |